Longboard Pharmaceuticals announced that the FDA has granted Rare Pediatric Disease designation and Orphan Drug designation for its investigational drug bexicaserin for the treatment of Dravet syndrome.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBPH:
- 3 Best Stocks to Buy Now, 9/18/2024, According to Top Analysts
- Longboard price target raised to $80 from $60 at H.C. Wainwright
- Longboard treatment of Dravet syndrome granted orphan designation
- Longboard Pharmaceuticals initiated with a Buy at Truist
- Longboard announces interim analysis results from OLE Phase 1b/2a PACIFIC study